Bleomycin pulmonary toxicity

Notably, drugs such as bleomycin are well-known for their potential to cause pulmonary toxicity, with incidence rates reaching up to 10% in

Bleomycin: pulmonary toxicity. Bleomycin: pulmonary toxicity Ann Intern Med. 2024 Apr;78(4):618. doi: 10.7326/ _1. Author R A Rudders

by H Shaikh 2024Bleomycin-induced pulmonary toxicity (BPT) is a serious and potentially fatal complication of bleomycin, a key component of Hodgkin lymphoma

by JG Yi 2024 Cited by 1Among cytotoxic drugs bleomycin is a prototype. Bleomycin-related pulmonary toxicity is usually known as dose-dependent and can be enhanced with concurrent

Pulmonary disease secondary to bleomycin occurs in as many as 40% of patients receiving the drug, 12 and a recent systematic review identified bleomycin exposure (along with alkylating agents) as a significant risk factor for long-term pulmonary toxicity. 13 Forty-one percent of childhood cancer survivors treated with bleomycin had abnormal

Bleomycin pulmonary toxicity is a direct consequence of free radical damage caused by bleomycin, iron, and oxygen forming a complex that cleaves cellular deoxyribonucleic acid (DNA). The lungs are at a higher risk of bleomycin-free radical damage because they lack the enzyme bleomycin hydrolase, which inactivates bleomycin.

Pulmonary toxicities occur in 10% of treated patients. In approximately 1%, the nonspecific pneumonitis induced by bleomycin progresses to pulmonary fibrosis

by LP Ozyigit 2024 Cited by 3Bleomycin pulmonary toxicity (BPT) is a potentially life-threatening consequence of bleomycin usage in patients. An overproduction of

All three developed bleomycin induced pulmonary toxicity in the form of pulmonary fibrosis during treatment of the disease. Mode of treatment, severity of the